Amgen Inc vs. Recursion Pharmaceuticals, Inc. Class A Common Stock
AMGN
Amgen Inc
$442.24 -0.36%
VS RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock
$3.46 +6.62%
Amgen Inc and Recursion Pharmaceuticals, Inc. Class A Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| AMGN | RXRX | |
|---|---|---|
| Market Cap | $239.95 billion | $1.74 billion |
| Revenue (TTM) | $38.09 billion | — |
| Net Income (TTM) | $8.74 billion | — |
AMGN leads on 1 of 1 size & scale factors.
Valuation
| AMGN | RXRX | |
|---|---|---|
| P/E Ratio | 27.47 | — |
| Price / Book | 20.53 | — |
| Price / Sales | 6.30 | — |
AMGN and RXRX split the valuation factors evenly.
Profitability
| AMGN | RXRX | |
|---|---|---|
| Net Margin | 22.95% | — |
| Return on Equity | 74.80% | — |
AMGN and RXRX split the profitability factors evenly.
Dividend
| AMGN | RXRX | |
|---|---|---|
| Dividend Yield | 2.28% | — |
| Payout Ratio | 62.61 | — |
AMGN and RXRX split the dividend factors evenly.
Risk & Sentiment
| AMGN | RXRX | |
|---|---|---|
| Short Interest | 1.66% | 0.29% |
RXRX leads on 1 of 1 risk & sentiment factors.
Dig deeper: AMGN overview, AMGN financials, RXRX overview, RXRX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.